Showing results (11-20 of 21) with videos related to

Sort By:
Pageof 3
Journal of Patient Experience|October 16, 2020
Mixed Messages: I. The Consequences of Communicating Negative Statements Within Emotional Support Messages to Cancer PatientsColter D Ray, Kory Floyd, Cris J Tietsort, et al.
The Journal of Pathology|May 30, 2013
Parallel evolution of tumour subclones mimics diversity between tumoursPierre Martinez, Nicolai Juul Birkbak, Marco Gerlinger, et al.
Nature Medicine|July 4, 2019
Publisher Correction: Combined BRAF and MEK inhibition with PD-1 blockade immunotherapy in BRAF-mutant melanomaAntoni Ribas, Donald Lawrence, Victoria Atkinson, et al.
Nature Medicine|June 8, 2019
Combined BRAF and MEK inhibition with PD-1 blockade immunotherapy in BRAF-mutant melanomaAntoni Ribas, Donald Lawrence, Victoria Atkinson, et al.
The Journal of Pathology|October 15, 2013
Ultra-deep T cell receptor sequencing reveals the complexity and intratumour heterogeneity of T cell clones in renal cell carcinomasMarco Gerlinger, Sergio A Quezada, Karl S Peggs, et al.
Nature Medicine|June 8, 2019
Dabrafenib, trametinib and pembrolizumab or placebo in BRAF-mutant melanomaPaolo Antonio Ascierto, Pier Francesco Ferrucci, Rosalie Fisher, et al.
Nature Genetics|February 4, 2014
Genomic architecture and evolution of clear cell renal cell carcinomas defined by multiregion sequencingMarco Gerlinger, Stuart Horswell, James Larkin, et al.
European Journal of Cancer (Oxford, England : 1990)|October 22, 2021
Crossover and rechallenge with pembrolizumab in recurrent patients from the EORTC 1325-MG/Keynote-054 phase III trial, pembrolizumab versus placebo after complete resection of high-risk stage III melanomaAlexander Mm Eggermont, Andrey Meshcheryakov, Victoria Atkinson, et al.
Genome Biology|August 28, 2014
Development of synchronous VHL syndrome tumors reveals contingencies and constraints to tumor evolutionRosalie Fisher, Stuart Horswell, Andrew Rowan, et al.
Nature Communications|March 20, 2015
Recurrent chromosomal gains and heterogeneous driver mutations characterise papillary renal cancer evolutionMichal Kovac, Carolina Navas, Stuart Horswell, et al.
Pageof 3